<DOC>
	<DOCNO>NCT00238407</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Docetaxel cisplatin may also make tumor cell sensitive radiation therapy . Giving docetaxel cisplatin together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give docetaxel cisplatin together radiation therapy work treat patient locally advanced esophageal cancer remove surgery .</brief_summary>
	<brief_title>Docetaxel , Cisplatin , Radiation Therapy Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine local tumor-control rate patient locally advance , unresectable esophageal cancer treat docetaxel , cisplatin , radiotherapy . Secondary - Determine feasibility regimen patient . - Determine adverse reaction regimen patient . - Determine local- distant-failure time local- distant-failure patient treated regimen . - Determine overall survival patient treat regimen . - Determine long-term survival rate patient treat regimen . - Determine whether early improvement dysphagia predictive marker patient treat regimen . - Determine quality life clinical benefit patient treat regimen . OUTLINE : This multicenter study . Patients receive docetaxel IV 30-60 minute cisplatin IV 1 hour day 1 , 22 , 43 , 50 , 57 , 64 , 71 . Beginning day 43 ( week 7 ) chemotherapy , patient undergo radiotherapy daily , 5 day week , 7 week . Quality life assess baseline , day 22 43 treatment , every 3 month 1 year completion study treatment . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 46 patient accrue study .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm esophageal cancer , include gastroesophageal junction Squamous cell adenocarcinoma Unresectable disease Meets 1 follow stag criterion endoscopic ultrasound : Cervical ( supraclavicular ) lesion , meet 1 follow stage : TX , N+ disease T34 , NX disease TX , NX , M1a* disease Thoracic ( celiac ) lesion , meet 1 follow stage : Unresectable T4 , NX disease TX , NX , M1a* disease Locally advance resectable tumor , inoperable due medical reason NOTE : *M1a require unequivocal abnormality stag CT scan/endosonography No T12 , N0 disease All tumor encompassable 1 radiation field No tumor esophagotracheal fistula PATIENT CHARACTERISTICS : Performance status WHO 01 Life expectancy Not specify Hematopoietic Neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ≤ 1.5 time upper limit normal ( ULN ) Bilirubin normal Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine clearance &gt; 60 mL/min Cardiovascular No myocardial infarction within past 3 month No New York Heart Association class III IV congestive heart failure No unstable angina pectoris No significant arrhythmias No severe cardiovascular disease Immunologic No uncontrolled active infection No active autoimmune disease Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study treatment No definite contraindication corticosteroids No uncontrolled diabetes mellitus No preexist peripheral neuropathy &gt; grade 1 No significant neurologic psychiatric disorder , include psychotic disorder , dementia , seizure , would preclude give informed consent No serious underlie medical condition would preclude study participation No prior concurrent malignancy except nonmelanoma skin cancer adequately treat carcinoma situ cervix PRIOR CONCURRENT THERAPY : Chemotherapy No prior chemotherapy Radiotherapy No prior radiotherapy chest Other More 30 day since prior experimental treatment another clinical trial No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>